Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials

被引：122

作者：

Andes, David ^{[1
]}

Kovanda, Laura ^{[2
]}

Desai, A. ^{[2
]}

Kitt, Therese ^{[2
]}

Zhao, M. ^{[1
]}

Walsh, Thomas J. ^{[3
,4
]}

机构：

[1] Univ Wisconsin, Madison, WI 53706 USA

[2] Astellas Pharma Global Dev Inc, Northbrook, IL USA

[3] Cornell Univ, Weill Cornell Med, New York Presbyterian Hosp, New York, NY 10021 USA

[4] Hosp Special Surg, Henry Schueler Fdn Scholar, 535 E 70th St, New York, NY 10021 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2018年 / 62卷 / 07期

关键词：

therapeutic drug monitoring; isavuconazole; REFERENCE LABORATORY EXPERIENCE; INVASIVE FUNGAL-INFECTIONS; EXPOSURE-RESPONSE; FILAMENTOUS FUNGI; VORICONAZOLE; POSACONAZOLE; EFFICACY; ASPERGILLUS; PHASE-3; SAFETY;

D O I：

10.1128/AAC.00585-18

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Clinical use of voriconazole, posaconazole, and itraconazole revealed the need for therapeutic drug monitoring (TDM) of plasma concentrations of these antifungal agents. This need for TDM was not evident from clinical trials. In order to establish whether this requirement also applies to isavuconazole, we examined the plasma concentrations of 283 samples from patients receiving isavuconazole in clinical practice and compared the values with those from clinical trials. The concentration distributions from real-world use and clinical trials were nearly identical (>1 mu g/ml in 90% of patients). These findings suggest that routine TDM may not be necessary for isavuconazole in most instances.

引用

页数：4

共 22 条

[1] Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications [J].

Andes, David ;

Pascual, Andres ;

Marchetti, Oscar .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (01) :24-34

[2]

Chin A, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/aac.00569-17, 10.1128/AAC.00569-17]

[3] Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi [J].

Desai, Amit ;

Kovanda, Laura ;

Kowalski, Donna ;

Lu, Qiaoyang ;

Townsend, Robert ;

Bonate, Peter L. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (09) :5483-5491

[4]

Desai AV, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.01034-17, 10.1128/aac.01034-17]

[5] Multicenter Study of Posaconazole Therapeutic Drug Monitoring: Exposure-Response Relationship and Factors Affecting Concentration [J].

Dolton, Michael J. ;

Ray, John E. ;

Chen, Sharon C. -A. ;

Ng, Kingsley ;

Pont, Lisa ;

McLachlan, Andrew J. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (11) :5503-5510

[6]

Imhof A, 2006, SWISS MED WKLY, V136, P739

[7] Exposure-Response of Posaconazole Used for Prophylaxis Against Invasive Fungal Infections: Evaluating the Need to Adjust Doses Based on Drug Concentrations in Plasma [J].

Jang, S. H. ;

Colangelo, P. M. ;

Gobburu, J. V. S. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (01) :115-119

[8] Toxicodynamics of Itraconazole: Implications for Therapeutic Drug Monitoring [J].

Lestner, Jodi M. ;

Roberts, Steven A. ;

Moore, Caroline B. ;

Howard, Susan J. ;

Denning, David W. ;

Hope, William W. .

CLINICAL INFECTIOUS DISEASES, 2009, 49 (06) :928-930

[9] Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial [J].

Maertens, Johan A. ;

Raad, Issam I. ;

Marr, Kieren A. ;

Patterson, Thomas F. ;

Kontoyiannis, Dimitrios P. ;

Cornely, Oliver A. ;

Bow, Eric J. ;

Rahav, Galia ;

Neofytos, Dionysios ;

Aoun, Mickael ;

Baddley, John W. ;

Giladi, Michael ;

Heinz, Werner J. ;

Herbrecht, Raoul ;

Hope, William ;

Karthaus, Meinolf ;

Lee, Dong-Gun ;

Lortholary, Olivier ;

Morrison, Vicki A. ;

Oren, Ilana ;

Selleslag, Dominik ;

Shoham, Shmuel ;

Thompson, George R., III ;

Lee, Misun ;

Maher, Rochelle M. ;

Schmitt-Hoffmann, Anne-Hortense ;

Zeiher, Bernhardt ;

Ullmann, Andrew J. .

LANCET, 2016, 387 (10020) :760-769

[10] Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis [J].

Marty, Francisco M. ;

Ostrosky-Zeichner, Luis ;

Cornely, Oliver A. ;

Mullane, Kathleen M. ;

Perfect, John R. ;

Thompson, George R., III ;

Alangaden, George J. ;

Brown, Janice M. ;

Fredricks, David N. ;

Heinz, Werner J. ;

Herbrecht, Raoul ;

Klimko, Nikolai ;

Klyasova, Galina ;

Maertens, Johan A. ;

Melinkeri, Sameer R. ;

Oren, Ilana ;

Pappas, Peter G. ;

Racil, Zdenek ;

Rahav, Galia ;

Santos, Rodrigo ;

Schwartz, Stefan ;

Vehreschild, J. Janne ;

Young, Jo-Anne H. ;

Chetchotisakd, Ploenchan ;

Jaruratanasirikul, Sutep ;

Kanj, Souha S. ;

Engelhardt, Marc ;

Kaufh, Achim ;

Ito, Masanori ;

Lee, Misun ;

Sasse, Carolyn ;

Maher, Rochelle M. ;

Zeiher, Bernhardt ;

Vehreschild, Maria J. G. T. .

LANCET INFECTIOUS DISEASES, 2016, 16 (07) :828-837

← 1 2 3 →